Advertisement

Pharmacologic Approaches to CDH: Evidence and Outcomes

  • Miguel J. A. Láinez
  • Ane Mínguez-Olaondo
Chapter

Abstract

Chronic daily headache (CDH) is a highly prevalent condition that severely affects patient’s lives. Most patients with CDH experience chronic migraine (CM). The management of these patients is complex and includes acute and preventive pharmacological treatment. In CDH, the use of acute medication should be restricted to avoid the risk of medication-overuse headache. However, the use of preventive medication should be considered in all patients with CDH. There are few studies investigating the role of preventives in CDH, and the majority have CM. Topiramate and onabotulinumtoxinA are the only two drugs with proved scientific evidence in the prevention of CM. There are other neuromodulators, beta-blockers, calcium channel blockers, or antidepressants useful in the management of this population of patients. We will present evidence for the efficacy of each drug and for recommended use.

Keywords

Chronic daily headache Chronic migraine Preventive treatment Topiramate OnabotulinumtoxinA Valproate sodium Gabapentin Propranolol Amitriptyline Fluoxetine Venlafaxine Candesartan Flunarizine Tizanidine 

References

  1. 1.
    Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23(8):820–4.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Sun-Edelstein C, Rapoport AM. Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep. 2016;20(1):6.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106(1–2):81–9.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Mathew NT, Kurman R, Perez F. Drug induced refractory headache--clinical features and management. Headache. 1990;30(10):634–8.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the head-HUNT study. Neurology. 2003;61(2):160–4.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol. 2007;7(6):383–93.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Becker WJ. The diagnosis and management of chronic migraine in primary care. Headache. 2017;57(9):1471–81.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Bagnato F, Good J. The use of antiepileptics in migraine prophylaxis. Headache. 2016;56(3):603–15.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    He A, Song D, Zhang L, Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain. 2017;18(1):26.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Aurora SK, Brin MF. Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 2017;57(1):109–25.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47(2):170–80.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814–23.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache. 2007;47(1):13–21.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Mei D, Ferraro D, Zelano G, Capuano A, Vollono C, Gabriele C, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006;29(5):269–75.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31(1):18–30.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291(8):965–73.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Silberstein SD. Topiramate in migraine prevention: a 2016 perspective. Headache. 2017;57(1):165–78.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455–64.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus. 2016;5:637.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251(8):943–50.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007;47(10):1398–408.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153–62.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17(2):103–8.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52(3):281–6.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–9.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008;9(1):37–41.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P, et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol. 2014;24(8):1289–97.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Gursoy AE, Ertas M. Prophylactic treatment of migraine. Noro Psikiyatr Ars. 2013;50(Suppl 1):S30–S5.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973–89.Google Scholar
  31. 31.
    Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;10(7):e0130733.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Perloff MD, Berlin RK, Gillette M, Petersile MJ, Kurowski D. Gabapentin in headache disorders: what is the evidence? Pain Med. 2016;17(1):162–71.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia. 2008;28(6):585–97.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33(1):35–9.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Pascual-Gomez J, Alana-Garcia M, Oterino A, Leira R, Lainez-Andres JM. Preventive treatment of chronic migraine with zonisamide: a study in patients who are refractory or intolerant to topiramate. Rev Neurol. 2008;47(9):449–51.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Pascual-Gomez J, Gracia-Naya M, Leira R, Mateos V, Alvaro-Gonzalez LC, Hernando I, et al. Zonisamide in the preventive treatment of refractory migraine. Rev Neurol. 2010;50(3):129–32.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Villani V, Ciuffoli A, Prosperini L, Sette G. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache. 2011;51(2):287–91.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Mohammadianinejad SE, Abbasi V, Sajedi SA, Majdinasab N, Abdollahi F, Hajmanouchehri R, et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol. 2011;34(4):174–7.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Beran RG, Spira PJ. Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (the Australian KEPPRA headache trial [AUS-KHT]). Cephalalgia. 2011;31(5):530–6.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523–32.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003;23(10):961–2.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Pascual J. Combination therapy for chronic migraine: bad news but not the last word. Neurology. 2012;78(13):940–1.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Edvardsson B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springerplus. 2013;2:479.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep. 2003;7(1):51–4.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Freitag FG, Lake A 3rd, Lipton R, Cady R, Diamond S, Silberstein S, et al. Inpatient treatment of headache: an evidence-based assessment. Headache. 2004;44(4):342–60.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Doyle Strauss L, Weizenbaum E, Loder EW, Rizzoli PB. Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study. Headache. 2016;56(10):1626–34.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Magalhaes E, Menezes C, Cardeal M, Melo A. Botulinum toxin type a versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg. 2010;112(6):463–6.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Couch JR. Amitriptyline versus placebo study G. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51(1):33–51.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–81.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Evans RW. A rational approach to the management of chronic migraine. Headache. 2013;53(1):168–76.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Saper JR, Silberstein SD, Lake AE 3rd, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994;34(9):497–502.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American academy of neurology and the American headache society. Neurology. 2012;78(17):1337–45.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107(1):44–8.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Tarlaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol. 2009;32(5):254–8.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. Duloxetine in the treatment of chronic migraine. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):49–54.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry. 2008;69(9):1449–54.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Saper JR, Lake AE, Tepper SJ. Nefazodone for chronic daily headache prophylaxis: an open-label study. Headache. 2001;41(5):465–74.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Gracia-Naya M, Rios C, Garcia-Gomara MJ, Sanchez-Valiente S, Mauri-Llerda JA, Santos-Lasaosa S, et al. A comparative study of the effectiveness of topiramate and flunarizine in independent series of chronic migraine patients without medication abuse. Rev Neurol. 2013;57(8):347–53.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Lai KL, Niddam DM, Fuh JL, Chen SP, Wang YF, Chen WT, et al. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Acta Neurol Scand. 2017;135(4):476–83.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–9.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Feher G, Pusch G. Role of antihypertensive drugs in the treatment of migraine. Orv Hetil. 2015;156(5):179–85.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42(6):470–82.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337–42.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016;17(1):106.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Cady RK, Saper J, Dexter K, Cady RJ, Manley HR. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Headache. 2015;55(4):529–42.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Bratbak DF, Nordgard S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia. 2017;37(4):356–64.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Saracco MG, Valfre W, Cavallini M, Aguggia M. Greater occipital nerve block in chronic migraine. Neurol Sci. 2010;31(Suppl 1):S179–80.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Dilli E, Halker R, Vargas B, Hentz J, Radam T, Rogers R, et al. Occipital nerve block for the short-term preventive treatment of migraine: a randomized, double-blinded, placebo-controlled study. Cephalalgia. 2015;35(11):959–68.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Inan LE, Inan N, Karadas O, Gul HL, Erdemoglu AK, Turkel Y, et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand. 2015;132(4):270–7.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Gul HL, Ozon AO, Karadas O, Koc G, Inan LE. The efficacy of greater occipital nerve blockade in chronic migraine: a placebo-controlled study. Acta Neurol Scand. 2016;136(2):138–44.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Cuadrado ML, Aledo-Serrano A, Navarro P, Lopez-Ruiz P, Fernandez-de-Las-Penas C, Gonzalez-Suarez I, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: a double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2016;37(9):864–72.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Cernuda-Morollon E, Pascual J. Something's moving in chronic migraine. Rev Neurol. 2014;58(1):1–3.PubMedPubMedCentralGoogle Scholar
  73. 73.
    D. Ezpeleta PPR. Guías diagnósticas y terpeútica de la Sociedad Española de Neurología 2015. 3. Guía oficial de práctica clínica en cefaleas2015 2015.Google Scholar
  74. 74.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Lia C, Tosi P, Giardini G, Caligiana L, Bottacchi E. Onabotulinumtoxin a for prophylaxis in chronic migraine: preliminary data from headache regional Centre of Aosta valley. Neurol Sci. 2014;35(Suppl 1):175–6.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from hull, U.K. J Headache Pain. 2014;15:54.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Grazzi L, Usai S. Onabotulinum toxin a (Botox) for chronic migraine treatment: an Italian experience. Neurol Sci. 2015;36(Suppl 1):33–5.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331(1–2):48–56.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, et al. Botulinum toxin type-a in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12(4):427–33.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med. 2015;8:79–86.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA injection on depression in chronic migraine. Headache. 2015;55(9):1218–24.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86(9):996–1001.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin a for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736–45.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51(1):21–32.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Castrillo Sanz A, Morollon Sanchez-Mateos N, Simonet Hernandez C, Fernandez Rodriguez B, Cerdan Santacruz D, Mendoza Rodriguez A, et al. Experience with botulinum toxin in chronic migraine. Neurologia. 2016;S0213-4853(16):30209–2.Google Scholar
  88. 88.
    Benatto MT, Florencio LL, Carvalho GF, Dach F, Bigal ME, Chaves TC, et al. Cutaneous allodynia is more frequent in chronic migraine, and its presence and severity seems to be more associated with the duration of the disease. Arq Neuropsiquiatr. 2017;75(3):153–9.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136(Pt 11):3489–96.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol. 2010;68(1):81–91.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Pagola I, Esteve-Belloch P, Palma JA, Luquin MR, Riverol M, Martinez-Vila E, et al. Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine. Rev Neurol. 2014;58(6):241–6.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Cernuda-Morollon E, Ramon C, Martinez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156(5):820–4.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Pedraza MI, de la Cruz C, Ruiz M, Lopez-Mesonero L, Martinez E, de Lera M, et al. OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm. Springerplus. 2015;4:176.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Oterino A, Ramon C, Pascual J. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. J Headache Pain. 2011;12(2):235–8.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Cephalalgia. 2015;35(10):864–8.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD. Onabotulinumtoxin-a treatment in Greek patients with chronic migraine. J Headache Pain. 2016;17(1):84.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, et al. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine. Eur J Neurol. 2014;21(6):851–9.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S. Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. BMC Neurol. 2015;15:100.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Aicua-Rapun I, Martinez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, et al. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin a during more than one year. J Headache Pain. 2016;17(1):112.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406–18.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Barbanti P, Aurilia C, Fofi L, Egeo G, Ferroni P. The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Neurol Sci. 2017;38(Suppl 1):31–5.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886–95.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6(6):534–47.  https://doi.org/10.1002/cpdd.345.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Hou M, Xing H, Cai Y, Li B, Wang X, Li P, et al. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. J Headache Pain. 2017;18(1):42.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87(1):41–8.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyNeurology Service, University Clinical Hospital, Catholic University of ValenciaValenciaSpain
  2. 2.Neurology ServiceUniversity Clinical Hospital, Catholic University of ValenciaValenciaSpain

Personalised recommendations